Cancer Monoclonal Antibodies - Market Insights, Competitive Landscape, and Market Forecast - 2030

Cancer Monoclonal Antibodies - Market Insights, Competitive Landscape, and Market Forecast - 2030

Cancer Monoclonal Antibodies Market by Type (Humanized Antibodies, Chimeric Antibodies, Murine Antibodies), Application (Blood Cancer, Breast Cancer, Liver Cancer, Colorectal Cancer, and Others), End-User (Hospitals, Research Institutions & Laboratories, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the rising cases of cancers and its risk factors globally.

The cancer monoclonal antibodies market was valued at USD 80.59 billion in 2023, growing at a CAGR of 10% during the forecast period from 2024 to 2030 to reach USD 156.59 billion by 2030. The demand for cancer monoclonal antibodies is primarily being boosted owing to the rising cases of cancers, the growing number of risk factors for cancers such as smoking, exposure to radiation, faulty lifestyle, and others, rising research and developmental activities by market players, during the forecast period from 2024 to 2030.

Cancer Monoclonal Antibodies Market Dynamics:

One of the key factors influencing the growth of the cancer monoclonal antibodies market is the rising number of cancer cases globally. According to the GLOBOCAN data (2024), the incidence of cancer was reported to be 19,976,499 worldwide in the year 2022. Lung and breast cancers accounted for the highest number of cancer cases in 2022 worldwide. Also, as per data cited by the World Health Organization 2022, worldwide around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020.

In addition, according to the data provided by GLOBOCAN 2021, worldwide around 19,292,789 new cancer cases were reported in 2020. As per the above-mentioned source, it has been estimated that worldwide there will be around 28,887,942 new cancer cases including 1.40 million new cases of liver, 3.63 million cases of lung, and 666 thousand new cases of kidney cancer, by 2040.

Owing to the presence of a large patient population associated with cancers worldwide, the diagnostic, drug discovery, and prognostic procedures along with the research and development activities are also expected to rise substantially, which would spur the market demand for cancer monoclonal antibodies. The increasing number of cancers globally would potentially require more cancer monoclonal antibodies for treatment to properly deliver an accurate treatment regimen for the cure of that particular type of cancer during the forecast period.

Also, as per the same source, the total number of people living with diabetes is projected to rise to 643 million by the year 2030 and 785 million by 2045 which will boost the market growth during the forecast period.

Owing to all the above-mentioned factors, the diagnosis rates for these diseases and treatment through cancer monoclonal antibodies are also expected to increase, which is thus expected to propel the market for cancer monoclonal antibodies market during the forecast period from 2024 to 2030.

However, stringent regulatory guidelines, and extensive and prolonged time exhaustive clinical trials for research, among others may act as significant restraints that are expected to limit the growth of the cancer monoclonal antibodies market during the forecast period.

Cancer Monoclonal Antibodies Market Segment Analysis:

Cancer Monoclonal Antibodies Market by Type (Humanized Antibodies, Chimeric Antibodies, Murine Antibodies), Application (Blood Cancer, Breast Cancer, Liver Cancer, Colorectal Cancer, and Others), End-User (Hospitals, Research Institutions & Laboratories, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the application segment of the cancer monoclonal antibodies market, the breast cancer category is estimated to amass a significant revenue share in the cancer monoclonal antibodies market in 2023. This can be attributed to the growing burden of breast cancers worldwide, increasing research and development activities, and key offerings, among others during the given forecast period.

In breast cancer, mAbs can perform a variety of functions, including targeting cancer cells, sometimes directly destroying them, assisting in the location and delivery of therapeutic medications to targets, slowing cell development, and suppressing immune system inhibitors, among others.

Monoclonal antibodies are also an important successful therapy strategy, particularly against HER2, although they have not been well studied for other kinds of breast cancer, including triple-negative breast cancer. Monoclonal antibodies limit antigen specificity, whereas bispecific and trispecific mAbs have opened the way to more targeted specific effectiveness. Monoclonal antibodies can be employed in a variety of ways and with greater efficacy than other forms of treatment, making them an ideal alternative for breast cancer treatment.

In February 2024, researchers at Tohoku University developed a novel monoclonal antibody specifically targeting a certain type of breast cancer cell. Their findings reported that the antibody disrupted their growth and proliferation while minimizing harm to surrounding healthy tissue.

Hence, owing to all the aforementioned factors, the market will experience an increased demand for breast cancer-based cancer monoclonal antibodies, thus driving the category growth in the overall cancer monoclonal antibodies market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall cancer monoclonal antibodies market:

North America is expected to account for the highest proportion of the Cancer Monoclonal Antibodies Market in 2023, out of all regions. This domination is due to the increasing prevalence of cancers, the increasing exposure to carcinogenic substances, smoking, radiation, and viruses, and recent regulatory approvals that act as a supportive factor in North America for the cancer monoclonal antibodies market growth.

According to the American Cancer Society (2022), in 2022, there were an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States. Further, as per the statistics revealed by the GLOBOCAN, approximately, 2,281,658 people were diagnosed with cancer in the US in 2020.

Moreover, the rising regulatory approvals for cancer monoclonal antibodies are also expected to boost the cancer monoclonal antibodies market in North America. For example, in October 2022, the U.S. Food and Drug Administration (FDA) approved a combination of the immunotherapy drugs durvalumab (Imfinzi®), a human monoclonal antibody, and the experimental drug tremelimumab for people with unresectable hepatocellular cancer.

Due to the high patient population base in North America, the preference for cancer monoclonal antibodies for treatment purposes is expected to increase the market demand for cancer monoclonal antibodies in the upcoming years. Thus, the interplay of all the above-mentioned factors will lead to an increase in the North America Cancer Monoclonal Antibodies market growth during the forecast period from 2024 to 2030.

Cancer Monoclonal Antibodies Market Key Players:

Some of the key market players operating in the Cancer Monoclonal Antibodies market include GSK plc, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Johnson and Johnson Services Inc., Spectrum Pharmaceuticals Inc., Eurofins Scientific, Genmab AS, Bristol Myers Squibb Company, Elli Lilly and Company, Amgen, Inc., AbbVie Inc., AstraZeneca Plc., CStone Pharmaceuticals, HiFiBiO Therapeutics, and others.

Recent Developmental Activities in the Cancer Monoclonal Antibodies Market:

In April 2024, announced the CE approval for the VENTANA® HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx* to identify metastatic breast cancer patients with low HER2 expression for whom ENHERTU® (trastuzumab deruxtecan) may be considered as a targeted treatment.

In December 2023, CStone Pharmaceuticals announced that the National Medical Products Administration (NMPA) of China approved the supplemental biologics license application (sBLA) for sugemalimab (Cejemly®) in combination with fluorouracil and platinum-based chemotherapy as first-line treatment of unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC). Sugemalimab became the world's first anti-PD-L1 monoclonal antibody approved for the first-line ESCC indication.

In December 2020, the FDA granted regular approval to margetuximab-cmkb (MARGENZA) ( Chinese hamster derived monoclonal antibody), in combination with chemotherapy, for the treatment of adult patients with HER2-positive (HER2+) metastatic breast cancer (MBC), who have received two or more prior anti-HER2 regimens.

Key Takeaways from the Cancer Monoclonal Antibodies Market Report Study

Market size analysis for current Cancer Monoclonal Antibodies Market size (2023), and market forecast for 6 years (2024 to 2030)

Top key offerings, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.

Key companies dominating the Cancer Monoclonal Antibodies market.

Various opportunities available for the other competitors in the Cancer Monoclonal Antibodies Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current Cancer Monoclonal Antibodies market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Cancer Monoclonal Antibodies market growth in the coming future?

Target Audience Who can be Benefited from This Cancer Monoclonal Antibodies Market Report Study

Cancer Monoclonal Antibody providers

Public and Private Corporate companies

Cancer Monoclonal Antibodies-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Providers dealing in Cancer Monoclonal Antibodies

Various corporates who want to know more about the Cancer Monoclonal Antibodies market and the latest offerings in the Cancer Monoclonal Antibodies market.

Frequently Asked Questions for the Cancer Monoclonal Antibodies Market:

1. What are Cancer Monoclonal Antibodies?

Cancer monoclonal antibodies are specialized proteins engineered to recognize and bind to specific oncologic targets with exceptional precision.

2. What is the market for Cancer Monoclonal Antibodies?

The cancer monoclonal antibodies market was valued at USD 80.59 billion in 2023, growing at a CAGR of 10% during the forecast period from 2024 to 2030 to reach USD 156.59 billion by 2030.

3. What are the drivers for the Cancer Monoclonal Antibodies market?

The Cancer Monoclonal Antibodies market is slated to witness prosperity owing to the rising cases of cancers, the growing number of risk factors for cancers such as smoking, exposure to radiation, faulty lifestyle, and others, rising research and developmental activities by global market players, during the forecast period from 2024 to 2030.

4. Who are the key players operating in the Cancer Monoclonal Antibodies market?

Some of the key market players operating in the Cancer Monoclonal Antibodies market include GSK plc, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Johnson and Johnson Services Inc., Spectrum Pharmaceuticals Inc., Eurofins Scientific, Genmab AS, Bristol Myers Squibb Company, Elli Lilly and Company, Amgen, Inc., AbbVie Inc., AstraZeneca Plc., CStone Pharmaceuticals, HiFiBiO Therapeutics, and others.

5. Which region has the highest share in the Cancer Monoclonal Antibodies market?

North America is expected to dominate the overall Cancer Monoclonal Antibodies market during the forecast period from 2024 to 2030. This domination is due to the increasing prevalence of cancers, the increasing exposure to carcinogenic substances, smoking, radiation, and viruses, and recent regulatory approvals that act as a supportive factor in North America for the cancer monoclonal antibodies market growth.